Your session is about to expire
← Back to Search
Ibrutinib for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing ibrutinib to treat patients with B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Non-Hodgkin's Lymphoma
- Transformed B-Cell Non-Hodgkin Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 201 Patients • NCT03053440Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a stroke or bleeding in the brain in the last 6 months.You have received vaccines with live, weakened viruses within 4 weeks before starting the treatment.You are taking a blood thinning medication called warfarin or other similar medications.You have had a transplant from someone else's cells and developed a condition called graft-versus-host disease (GVHD) that required medication to suppress your immune system.
- Group 1: Treatment (ibrutinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Ibrutinib received certification from the Federal Drug Administration?
"Based on the information that we have, our team has assigned Ibrutinib a score of 2 for safety. This is due to its status as a Phase 2 trial; while there are some data backing up safety claims, none exist in regards to efficacy."
What is the enrollment size of this experiment?
"This trial has ceased to recruit participants. It was initially posted on October 1st 2014 and last edited on September 26th 2022. At present, there are 1766 studies looking for people with lymphoma, B-Cell, and 155 studies searching for Ibrutinib patients."
Are there opportunities for enrollment in this investigation?
"Currently, this trial is not enrolling new patients. The initial post was made on October 1st 2014 and the last update occurred on September 26th 2022. For those looking for other research opportunities, there are 1766 studies recruiting for lymphoma b-cell trials as well as 155 pertaining to Ibrutinib treatment actively seeking enrolment."
Share this study with friends
Copy Link
Messenger